• English
    X

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    Maryland Department of Health
    Newsroom

    ​
    First Maryland Case of Bleeding Reported in User of Synthetic Cannabinoids
     
    Baltimore, MD (April 5, 2018) — The Maryland Poison Center and the Maryland Department of Health are warning the public of the danger of bleeding that can be linked to use of synthetic cannabinoids, also known as spice, K2, or fake weed.
     
    The Maryland Poison Center at the University of Maryland School of Pharmacy was notified of a case in which a user of synthetic cannabinoids experienced bleeding and was hospitalized on April 3, 2018.
     
    The symptoms in the Maryland case are similar to the description of dozens of cases in the Chicago region reported over the past three weeks to the Illinois Poison Center. Persons in the Chicago area reported recent use of synthetic cannabinoids prior to their illness. At least two of those cases have resulted in death. The condition is known as synthetic cannabinoid-associated coagulopathy.
     
    In the Maryland case, the Maryland Poison Center became involved after a person in Central Maryland was hospitalized to treat bleeding and coagulation issues.
     
    The Maryland Poison Center and the Maryland Department of Health have begun taking steps to notify the public, first responders and clinicians in the event that other cases arise in Maryland.
     
    Clinical signs from the Illinois and Maryland cases include bruising, nosebleeds, bleeding of the gums, bleeding out of proportion to the level of injury, vomiting blood, blood in urine or stool, or excessively heavy menstrual bleeding and back pain.
     
    “We’re warning people to not use synthetic cannabinoids,” says Bruce Anderson, PharmD, DABAT, executive director of the Maryland Poison Center. “While never safe, the recent increased risk of adverse effects such as synthetic cannabinoid-associated coagulopathy makes it critical for people to abstain.”
     
    If anyone who has used synthetic cannabinoids develops significant unexplained bleeding, it is recommended they:
    • Seek immediate medical care at a hospital.
    • Contact the Maryland Poison Center at 800-222-1222.
     
    Media who wish to interview Dr. Anderson are asked to contact Patricia Fanning, senior media relations specialist, 410-706-7946 (office) or 443-615-5811 (mobile) or email: pfanning@umaryland.edu at the University of Maryland, Baltimore.  

    ###